Xenotransplantation: CRISPR-Edited Pig Hearts and the Race to Solve the Organ Shortage

17 People Die Every Day Waiting for an Organ—Pigs May Change That

Over 100,000 Americans are on the national organ transplant waiting list at any given time. Seventeen die each day while waiting. Globally, the disparity between organ demand and donation is so severe that transplant tourism and organ trafficking persist despite international prohibition. The radical proposed solution—replacing failed human organs with those from genetically modified pigs—has moved from science fiction to clinical trial within a single decade. In January 2022, surgeons at the University of Maryland transplanted a CRISPR-edited pig heart into a living human patient. He survived for 60 days. The era of xenotransplantation has begun; its ultimate viability remains the most consequential open question in medicine.

Why Pigs? The Biological Case

Pigs are the preferred xenotransplantation source for several practical and biological reasons. Their organ sizes are anatomically compatible with adult humans. They reach reproductive maturity quickly and produce large litters, enabling scalable supply. Pig physiology shares significant overlap with human physiology in cardiovascular function, renal filtration, and metabolic rates. And critically, pig genomes can now be edited with CRISPR-Cas9 at dozens of sites simultaneously, allowing researchers to remove incompatibility signals and add human compatibility factors.

Primates—anatomically closer to humans—were abandoned as primary xenotransplantation candidates because of ethical concerns, slow breeding, small litter sizes, and paradoxically higher immunological barriers due to evolutionary proximity triggering immune recognition.

The Rejection Problem: Three Immunological Barriers

Current state-of-the-art genetically modified pigs—developed by companies including eGenesis, Revivicor, and United Therapeutics—carry up to 69 genetic modifications. These include knocking out 3 pig sugar antigen genes, inactivating all 59 copies of porcine endogenous retroviruses (PERVs), and inserting up to 7 human genes to promote compatibility and suppress immune responses. The 2022 University of Maryland patient received a heart from a Revivicor pig with 10 genetic modifications.

The Viral Contamination Challenge

All pig cells contain porcine endogenous retroviruses—viral sequences integrated into the pig genome millions of years ago. In laboratory conditions, PERVs have been shown to infect human cells. The concern: a xenotransplant recipient receiving prolonged immunosuppression could potentially develop PERV-related disease, or worse, serve as a mixing vessel for novel viral reassortants. In 2017, the CRISPR pioneer George Church's laboratory at Harvard published the first pig cells with all 62 PERV copies inactivated using CRISPR, a technical feat that removed a significant biosafety concern. eGenesis has incorporated PERV inactivation into its pig lines as a standard platform feature.

Landmark Clinical Cases

• January 2022: David Bennett Sr., 57, University of Maryland—received 10-gene-edited pig heart. Survived 60 days; autopsy later revealed porcine cytomegalovirus was present in the organ despite testing protocols, possibly contributing to cardiac failure.
• July 2023: University of Maryland performed a second pig heart transplant in Lawrence Faucette, 58. He survived 40 days.
• March 2024: Massachusetts General Hospital transplanted a genetically modified pig kidney from eGenesis into a 62-year-old patient with end-stage renal disease. He survived nearly two months before dying of unrelated complications.
• 2021 (NYU Langone): A pig kidney was attached to the blood vessels of a brain-dead human for 54 hours, producing urine normally without rejection—a controlled proof-of-concept that preceded the clinical transplants.

The Regulatory and Ethical Landscape

The FDA issued draft guidance for xenotransplantation clinical trials in 2016, requiring rigorous infectious disease screening, long-term surveillance of recipients and close contacts, and tissue banking for retrospective analysis. Current trials operate under Investigational New Drug applications with extensive biosafety review. The FDA's March 2023 xenotransplantation advisory committee meeting identified monitoring for novel pathogens as the most critical unresolved issue, given that no surveillance program can anticipate unknown viral risks.

• Recipients must consent to lifelong post-transplant monitoring and contact tracing of close contacts.
• Xenotransplant tissue and organs cannot be donated after the recipient's death; this limits the ability to pass organs from one recipient to another.
• International coordination is required: the WHO and national health ministries track xenotransplant recipients as a novel infectious disease surveillance population.

The Path Forward

Most transplant immunologists believe the technical barriers to pig kidney xenotransplantation are closer to resolution than those for the heart, liver, or lung. The kidney's simpler rejection biology and the availability of dialysis as a bridge therapy make kidney xenotransplantation the most likely first approved indication. Heart xenotransplantation faces the additional challenge that the transplanted heart must work immediately and sustain cardiac output under physiological stress—there is no heart-lung bypass equivalent for home use. Liver xenotransplantation faces metabolic compatibility challenges: pig liver produces some proteins incompatible with human physiology. Current timelines from leading research groups suggest FDA approval of a pig kidney xenotransplant for selected end-stage renal disease patients is plausible within 5–10 years if current trials demonstrate durable function beyond six months.